[en] We evaluated 10/10 HLA antigen-matched unrelated hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning with fludarabine 3 x 30 mg/m(2) and 2 Gy of total body irradiation as treatment for patients with chronic myeloid leukemia who were ineligible for conventional HCT. Data from 21 consecutive patients in first chronic phase (CP1; n = 12), accelerated phase (AP; n = 5), second CP (CP2; n = 3), and blast crisis (n = 1) were analyzed. Stem cell sources were bone marrow (n = 4) or granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMCs; n = 17). The patient who underwent transplantation in blast crisis died on day 21 (too early to be evaluated. for engraftment) from progressive disease. Sustained engraftment was achieved in 5 of 12 patients who underwent transplantation in CP1, 4 of 5 patients who underwent transplantation in AP, and 2 of 3 patients who underwent transplantation in CP2, whereas 9 patients rejected their grafts between 28 and 400 days after HCT. Specifically, I of 4 marrow recipients and 10 of 17 G-PBMC recipients achieved sustained engraftment. Graft rejections were nonfatal in all cases and were followed by autologous reconstitution with persistence or recurrence of chronic myeloid leukemia. Seven of 11 patients with sustained engraftment-including all 5 patients in CP 1, 2 of 4 patients in AP, and neither of the 2 patients in CP2-were alive in complete cytogenetic remissions 118 to 1205 days (median, 867 days) after HCT. Two of the remaining 4 patients died of nonrelapse causes in complete (n = 1) or major (n = 1) cytogenetic remissions, and 2 died of progressive disease. Further efforts are directed at reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplantation immunosuppression. (c) 2005 American Society for Blood and Marrow Transplantation.
Disciplines :
Immunology & infectious disease Hematology Surgery
Author, co-author :
Baron, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie
T.P. Hughes J. Kaeda S. Branford et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423-1432
R. Bhatia M. Holtz N. Niu et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 101 2003 4701-4707
J.M. Goldman Chronic myeloid leukemia - Still a few questions [review] Exp Hematol 32 2004 2-10
P.L. Weiden N. Flournoy E.D. Thomas et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts N Engl J Med 300 1979 1068-1073
R.L. Truitt The Mortimer M. Bortin Lecture: To destroy by the reaction of immunity - The search for separation of graft-versus-leukemia and graft-versus-host Biol Blood Marrow Transplant 10 2004 505-523
J.T. Slattery R.A. Clift C.D. Buckner et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation Blood 89 1997 3055-3060
B.S. Andersson A. Kashyap D. Couriel et al. Intravenous busulfan in pretransplant chemotherapy: Bioavailability and patient benefit Biol Blood Marrow Transplant 9 2003 722-724
J.P. Radich T. Gooley W. Bensinger et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen Blood 102 2003 31-35
J.A. Hansen T.A. Gooley P.J. Martin et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia N Engl J Med 338 1998 962-968
P.B. McGlave X.O. Shu W. Wen et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program Blood 95 2000 2219-2225
D.J. Weisdorf C. Anasetti J.H. Antin et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: Comparative analysis of unrelated versus matched sibling donor transplantation Blood 99 2002 1971-1977
D.L. Porter R.H. Collins Jr O. Shpilberg et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions Biol Blood Marrow Transplant 5 1999 253-261
H.J. Kolb C. Schmidt A.J. Barrett D.J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood 103 2004 767-776
R. Wong S.A. Giralt T. Martin et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years Blood 102 2003 3052-3059
H. Khoury D. Adkins R. Brown et al. Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen Biol Blood Marrow Transplant 7 2001 352-358
R. Chakraverty K. Peggs R. Chopra et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood 99 2002 1071-1078
R. Or M.Y. Shapira I. Resnick et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase [comment in Blood 2003;101:5084; author reply 5084-5085] Blood 101 2003 441-445
P.A. McSweeney D. Niederwieser J.A. Shizuru et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
E. Sloand R.W. Childs S. Solomon A. Greene N.S. Young A.J. Barrett The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia Bone Marrow Transplant 32 2003 897-901
T. Lange M. Deininger R. Brand et al. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning Leukemia 18 2004 1468-1475
L.C. Feinstein B.M. Sandmaier D.G. Maloney et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant Biol Blood Marrow Transplant 9 2003 266-272
M. Uzunel J. Mattsson M. Brune J.E. Johansson J. Aschan O. Ringden Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation Blood 101 2003 469-472
Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. In press
P.A. McSweeney R. Storb Mixed chimerism: Preclinical studies and clinical applications [review] Biol Blood Marrow Transplant 5 1999 192-203
D. Niederwieser M. Maris J.A. Shizuru et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood 101 2003 1620-1629
M.B. Maris D. Niederwieser B.M. Sandmaier et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 102 2003 2021-2030
J.P. Radich T. Gooley E. Bryant et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation Blood 98 2001 1701-1707
Baron F, Little MT, Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev. In press
F.R. Kerbauy T. Lange T. Gooley et al. Non-myeloablative allografting from HLA-identical sibling donors for treatment of CML [abstract 2316] Blood 104 pt 1 2004 637a
D.W. Niederwieser U. Hegenbart B.M. Sandmaier et al. Treatment for acute myelogenous leukemia by low dose irradiation based conditioning and hematopoietic cell transplantation from related and unrelated donors [abstract 3074] Blood 104 pt 1 2004 840a
M. Bornhauser C. Thiede U. Platzbecker et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients Clin Cancer Res 7 2001 2254-2262
C. Hallemeier Re: High rate of graft failure in 25 patients with chronic myelogenous leukemia conditioned with a reduced-intensity regimen of 550 cGy total body irradiation and cyclophosphamide for unrelated donor transplantation [letter to the editor] Biol Blood Marrow Transplant 10 2004 726-727
F. Baron M. Maris B. Storer et al. Higher doses of transplanted CD34+, CD3+ and CD8+ cells are associated with better donor T-cell chimerism and less graft rejection, but not with GVHD after nonmyeloablative conditioning for unrelated hematopoietic cell transplantation [abstracct 2753] Blood 104 pt 1 2004 735a
C. Yu R. Storb B. Mathey et al. DLA-identical bone marrow grafts after low-dose total body irradiation: Effects of high-dose corticosteroids and cyclosporine on engraftment Blood 86 1995 4376-4381
R. Storb C. Yu J.L. Wagner et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 1997 3048-3054
F. Baron J.E. Baker R. Storb et al. Kinetics of engraftment in patients with hematological malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning Blood 104 2004 2254-2262
B.M. Sandmaier D.G. Maloney M.B. Maris et al. Conversion of low donor chimerism following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT) using pentostatin and donor lymphocyte infusion (DLI) [abstract] Blood 104 2004 57a